TABLE 3.

Proportions and Incidence Rates of Malignancies (Excluding Nonmelanoma Skin Cancer) of Interest in the Overall Cohort_a

	Tofacitinib All	Predominant-dose Tofacitinib 5 mg Twice Daily	Predominant-dose Tofacitinib 10 mg Twice Daily
Total number of patients	1124	198	926
Primary analysis
Total PY of exposure	2576.4	664.1	1912.2
Patients with events, n (%)	20 (1.8)	3 (1.5)	17 (1.8)
IR (95% CI)	0.75 (0.46–1.16)	0.44 (0.09–1.29)	0.86 (0.50–1.38)
Colorectal cancer
Total PY of exposure	2661.70	677.87	1983.83
Patients with events, n (%)	2 (0.2)	0 (0.0)	2 (0.2)
IR (95% CI)	0.08 (0.01–0.27)	0.00 (0.00–0.54)	0.10 (0.01–0.36)
Lymphoma and lymphoproliferative disease
Total PY of exposure	2661.76	677.76	1984.00
Patients with events, n (%)	2 (0.2)	1 (0.5)	1 (0.1)
IR (95% CI)	0.08 (0.01–0.27)	0.15 (0.00–0.82)	0.05 (0.00–0.28)

Abbreviations: CI, confidence interval; IR, incidence rate (unique patients with event per 100 PY of exposure); n, number of patients with the event; PY, patient-years.

^aAll events, including those that are outside the 28-day risk period, are included.